Citation:
Ding JC, Montemayor-Garcia C, Stotler BA, Spitalnik SL, Méndez JA. Rh disease in Mexico: evaluating regional and institutional differences in treatment availability and disease management: Rh disease awareness in Mexico. Blood Transfusion. 2025;23(2):109-17. PMID: 391336 PMCID: PMC11925255 DOI: 10.2450/BloodTransfus.750
Summary:
A significant burden of Rh disease still exists in Mexico. To examine disparities in the allocation of maternal and child health resources, as well as clinical knowledge regarding Rh disease, a questionnaire was sent to all Mexican obstetricians-gynecologists. Significant regional variations in prevention and treatment were found, particularly with regard to providing anti-RhD immunoglobulin to prevent alloimmunization. Closing the gap in the availability of anti-RhD immunoglobulin should take priority in future efforts aimed at providing equitable care, because this will yield the preferred outcome of preventing Rh disease, rather than needing to use more complex measures to treat Rh disease after it develops. These results can inform strategies to understand and eliminate these healthcare disparities.